ALCOHOL CUE HUMAN LABORATORY STUDY TESTING ASP 8062

这项研究的主要目的是评估ASP8062，每天一次25毫克和匹配的安慰剂，在人类实验室的范例中，在中重度酒精使用障碍患者中每天服用2周后对酒精诱导的酒精渴望的影响，这是被《精神疾病诊断和统计手册-第五版》(DSM-5™)证实的。次要目标包括评估ASP8062，每天25毫克，以及配对的安慰剂，在研究的最后4周内减少酒精消费、酒精渴求、吸烟(在吸烟者中)和尼古丁使用(在尼古丁使用者中)、情绪、睡眠、酒精使用的负面后果、研究保留以及安全性和耐受性。

The primary objective of this study is to evaluate the effects of ASP8062, 25 mg once a day and matched placebo, on alcohol cue-elicited alcohol craving during a human laboratory paradigm after 2 weeks of daily dosing among subjects with moderate to severe alcohol use disorder (AUD) as confirmed by the Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5™). Secondary objectives include evaluation of ASP8062, 25 mg once a day, and matched placebo on reduction of alcohol consumption, alcohol craving, cigarette smoking (among smokers) and nicotine use (among nicotine users), mood, sleep, alcohol use negative consequences, study retention, and safety and tolerability throughout the last 4 weeks of the treatment phase of the study.